Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing By: Investor Brand Network January 12, 2024 at 15:30 PM EST Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs… Human clinical studies have been conducted since 2018, with more on the way,” a recent article reads. “With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets, and more.” To view the full article, visit https://ibn.fm/V8gM5 About Lexaria Bioscience Corp. Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX About TinyGems TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.TinyGems.com Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer TinyGemsLos Angeles, CAwww.TinyGems.com310.299.1717 OfficeEditor@TinyGems.com TinyGems is powered by IBN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing By: Investor Brand Network January 12, 2024 at 15:30 PM EST Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs… Human clinical studies have been conducted since 2018, with more on the way,” a recent article reads. “With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets, and more.” To view the full article, visit https://ibn.fm/V8gM5 About Lexaria Bioscience Corp. Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX About TinyGems TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.TinyGems.com Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer TinyGemsLos Angeles, CAwww.TinyGems.com310.299.1717 OfficeEditor@TinyGems.com TinyGems is powered by IBN
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs… Human clinical studies have been conducted since 2018, with more on the way,” a recent article reads. “With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets, and more.” To view the full article, visit https://ibn.fm/V8gM5 About Lexaria Bioscience Corp. Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX About TinyGems TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.TinyGems.com Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer TinyGemsLos Angeles, CAwww.TinyGems.com310.299.1717 OfficeEditor@TinyGems.com TinyGems is powered by IBN